LON:EDEN Eden Research (EDEN) Share Price, News & Analysis GBX 3.51 -0.09 (-2.50%) As of 05/5/2026 12:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Eden Research Stock (LON:EDEN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eden Research alerts:Sign Up Key Stats Today's Range 3.40▼ 3.6050-Day Range 2.71▼ 452-Week Range 1.96▼ 5Volume310,009 shsAverage Volume660,044 shsMarket Capitalization£21.53 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries. Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has two products currently on the market: Based on plant-derived active ingredients, Mevalone ® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally. Cedroz ™ is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally. Eden's Sustaine ® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation. Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services. For more information about Eden, please visit: www.edenresearch.com . Read More Receive EDEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eden Research and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EDEN Stock News HeadlinesEden Research seals equity raise, investors eye expedited commercialisationApril 10, 2026 | finance.yahoo.comEden Research hails Chile approval of grape fungicideJanuary 9, 2026 | lse.co.ukYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today. | Profits Run (Ad)SunOpta: Q3 Earnings SnapshotNovember 5, 2025 | finance.yahoo.comEden Research Share Chat (EDEN)October 31, 2025 | lse.co.ukEden Research (LON:EDEN) Is In A Good Position To Deliver On Growth PlansOctober 29, 2025 | finance.yahoo.comHere’s how body image is quietly shaping American lives, new survey revealsOctober 23, 2025 | nypost.comNSurvey Reveals Percentage Of Americans Who Can't Look In Mirror Without Negative ThoughtsOctober 23, 2025 | msn.comSee More Headlines EDEN Stock Analysis - Frequently Asked Questions How have EDEN shares performed this year? Eden Research's stock was trading at GBX 2.80 at the start of the year. Since then, EDEN stock has increased by 25.4% and is now trading at GBX 3.51. How were Eden Research's earnings last quarter? Eden Research plc (LON:EDEN) posted its quarterly earnings results on Wednesday, September, 17th. The company reported ($0.25) EPS for the quarter. Eden Research had a negative trailing twelve-month return on equity of 20.99% and a negative net margin of 65.01%. How do I buy shares of Eden Research? Shares of EDEN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Eden Research own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eden Research investors own include Kromek Group (KMK), Primary Health Properties (PHP), National Grid (NG.L), Cabot Energy (CAB), EPE Special Opportunities (ESO), Marston's (MARS) and Mothercare (MTC). Company Calendar Last Earnings9/17/2025Today5/05/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorBasic Materials Industry Agricultural Inputs Sub-IndustryN/A Current SymbolLON:EDEN CIKN/A Webwww.edenresearch.com Phone+44-1285-359555FaxN/AEmployees19Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£1.52 million Net Margins-65.01% Pretax MarginN/A Return on Equity-20.99% Return on Assets-11.29% Debt Debt-to-Equity Ratio5.41 Current Ratio2.17 Quick Ratio2.42 Sales & Book Value Annual Sales£3.62 million Price / Sales5.96 Cash FlowGBX 0.29 per share Price / Cash Flow11.90 Book ValueGBX 2.38 per share Price / Book1.47Miscellaneous Outstanding Shares613,363,000Free FloatN/AMarket Cap£21.53 million OptionableNot Optionable Beta0.92 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (LON:EDEN) was last updated on 5/6/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHow to collect $1,170/month from silverThere is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...Investors Alley | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredDid you miss The Dark AI Summit?Over 55,000 people attended Jeff Brown's Dark AI Summit, where he revealed a private AI company he believes ho...Brownstone Research | SponsoredWhy Elon just bought a power plant (Ticker inside)Elon Musk is burning nearly $1 billion a month because he cannot power the world's largest supercomputer witho...Behind the Markets | SponsoredIran War Update: Trump’s Hand-Written Letter Reveals What Comes NextJim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eden Research plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Eden Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.